Monsenso

What Monsenso does

Monsenso A/S is a Danish digital-health company, founded in 2013 and headquartered in Frederiksberg (Copenhagen), Denmark, with a UK subsidiary in London. It develops and commercialises a CE-marked Class 1 medical-device platform — the Monsenso digital health solution — that connects three user groups (patients, family caregivers, and clinicians) through a patient smartphone app (iOS/Android), a companion carer app, and a clinician web portal (Monsenso Clinic). The platform continuously captures electronic Patient-Reported Outcomes (ePRO), ecological momentary assessment data, and passive smartphone and wearable sensor signals (activity, mobility, geolocation, phone/SMS usage, voice features extracted via openSMILE, and sleep) to compute digital biomarkers, predict mood instability, surface early-warning signs, and deliver personalised treatment support for conditions including depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, and addiction.

The company operates a triple-loop architecture (patient–carer–clinician) that is the technological extension of the EU-funded MONARCA research project (MONARCA I/II), and it underpins a 40+ publication evidence base in journals such as Translational Psychiatry, JMIR, and Acta Psychiatrica Scandinavica. Its go-to-market is sales-led and enterprise-focused, with named deployments including the Municipality of Ikast-Brande's Center for Rusmiddelbehandling (addiction pilot, 2019–2020), Mental Health Services Southern Denmark (30-patient anxiety feasibility study), PsykiatriResurs Sweden, and a ~1,000-individual schizophrenia triple-loop deployment. Revenue is generated through quote-based enterprise subscriptions to healthcare providers, municipalities, and private clinics; through a Life Sciences line offering real-world data collection and a digital companion / digital adjunct for pharmaceutical partners; and through research-project partnerships with CROs and academic institutions (PhaseV, DECODE, PERSONAE, MentBest, Smart-Bipolar). Pricing is not publicly disclosed. Monsenso is publicly listed (IPO in 2020) and holds a regulatory stack spanning CE Class 1, UKCA, ISO 13485:2016, ISO 27001, UK Cyber Essentials, HIPAA, and GDPR.

Name

Monsenso

Legal name

Monsenso A/S

Website

https://monsenso.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Monsenso A/S is a publicly listed Danish digital-health company that sells a CE-marked Class 1 medical-device platform — a triple-loop patient/carer/clinician system capturing smartphone, wearable, and self-reported data — to mental-healthcare providers, municipalities, pharmaceutical firms, CROs, and academic researchers across Europe, the UK, and the US.

Ownership category

akta.pro rank

Product category

Digital Mental Health Software

NAICS

Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG)

akta.pro secondary industries

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Psychiatry & Medication Management Platforms (HLALAEAB), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

Keywords

• Digital mental health platform
• Remote patient monitoring
• Behavioral health software
• Real-world data collection
• Clinical decision support

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Digital health platform subscriptions to healthcare providers: Monsenso offers its CE-marked Class 1 medical device digital health platform to healthcare, social care, and life sciences organisations. Although pricing is not publicly disclosed, the platform is deployed at hospitals, municipalities, and clinics for remote patient monitoring, decentralised clinical trials, and treatment support, consistent with B2B SaaS / enterprise licensing with recurring revenue.
2. Real-world data and digital companion services for pharma: Life Sciences offering bundles the Monsenso solution as a digital companion / digital adjunct to medication for pharma customers, enabling collection of real-world patient data for scientific and commercial insight. Pharma clients use the platform to improve treatment adherence and to gather real-world evidence, supporting a managed services / data monetisation overlay on top of the core subscription.
3. Research project and clinical study partnerships: Monsenso provides the digital backbone for decentralised, real-world clinical studies (e.g., PhaseV supported by Innovation Fund Denmark, RADMIS, MONARCA I/II, DECODE, PERSONAE, MentBest, Smart-Bipolar). Revenue is generated via research collaboration and project-based delivery, often co-funded by public innovation funds.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Monsenso provides a CE-marked Class 1 medical-device digital health platform for mental health that captures real-world patient data via a smartphone app (ePRO plus passive smartphone and wearable sensor data), surfaces it to clinicians through a web portal, and involves family caregivers through a paired app — the so-called triple-loop model. The platform is sold to healthcare providers, municipalities, pharmaceutical companies, insurance firms, CROs, and academic researchers for remote patient monitoring, treatment support, relapse prevention, decentralised clinical trials, and real-world evidence generation.

Product overview

Monsenso offers a single integrated CE-marked Class 1 medical-device digital health platform (the "Monsenso digital health solution") rather than a portfolio of disconnected products. The core platform is composed of three tightly coupled modules: the Monsenso Patient App for individuals (collecting self-reported ePRO and passive smartphone/wearable sensor data), the Monsenso Clinician Web Portal ("Monsenso Clinic") for healthcare providers (viewing aggregated data, triaging patients, and personalising treatment), and the Monsenso Carer App that completes the triple-loop model by involving family caregivers. On top of this core, Monsenso sells two additional offerings under its Life Sciences line: a Real-World Data (RWD) module for decentralised clinical studies and a Digital Companion offering positioned as a digital adjunct to medication for pharmaceutical partners. The solution is also deployed via the PhaseV national innovation programme and supports research projects such as MONARCA I/II, RADMIS, DECODE, PERSONAE, MentBest and Smart-Bipolar.

Differentiator

Problem solved

Functional benefit

Brands

• Monsenso mHealth Solution: Core digital health platform comprising a smartphone application for patients (and family carers) and a web portal for clinicians, used for remote monitoring, treatment support, decentralised trials, and real-world data collection in mental health.
• Monsenso Clinic

Products and services

• Monsenso Digital Health Solution CE-marked Class 1 medical-device digital health platform that captures real-world patient data from smartphones and wearables (ePRO plus passive sensor data including activity, mobility, voice, sleep) and surfaces it to clinicians via a web portal and to family caregivers via a paired app. Sold to healthcare providers, municipalities, pharmaceutical companies, insurance firms, CROs, and academic researchers for remote patient monitoring, treatment support, relapse prevention, decentralised clinical trials, and real-world evidence generation in mental health and psychiatry.
• Real-World Data (RWD) offering Life-sciences offering that leverages the Monsenso platform to collect real-world, decentralised patient-reported and behavioural data for clinical studies and post-market evidence generation in mental health, supporting pharma and CRO customers with objective, continuous data outside of clinic visits.
• Digital Companion (Pharma offering) Digital companion offered to healthcare professionals by pharmaceutical partners as a digital adjunct to medication, aimed at improving treatment adherence and providing real-world data for new scientific and commercial insight in mental health therapies.

Quantifiable outcome

• 1,000-individual schizophrenia deployment using triple-loop mHealth solution
• +5 more outcomes

Named customers4 records

Segments8 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability9 records

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship — flagship danish municipal deployment and reference customer, core — clinical reference site in sweden, core — clinical trial partner and flagship — flagship clinical research collaboration underpinning monsenso's evidence base.

• Municipality of Ikast-Brande (Center for Rusmiddelbehandling)flagship — flagship danish municipal deployment and reference customerStrategic or Co-development Partner · 17 January 2019January 2019–January 2020 pilot integrating Monsenso into outpatient alcohol and substance misuse treatment at Ikast-Brande municipality's Center for Rusmiddelbehandling. The collaboration evaluates clinical and financial benefits of digital monitoring for clients in active treatment and post-treatment relapse prevention.
• PsykiatriResurs (Gothenburg, Sweden)core — clinical reference site in swedenImplementation/ SI/ Consulting Partner · 30 August 2018Swedish psychiatrist Kristoffer Södersten at PsykiatriResurs uses the Monsenso mHealth solution in his clinical psychiatric practice and is featured as a customer story on the website, explaining how Monsenso improves diagnosis and follow-up treatment.
• Bureau Veritas Certification Denmark A/S1 June 2018
• Mental Health Services in the Region of Southern Denmark (MHS)core — clinical trial partnerStrategic or Co-development Partner · 26 January 2016Collaboration on 'The Anxiety Monitoring Study' — feasibility study of the Monsenso mHealth solution in 30 anxiety patients, with the goal of supporting a future randomised controlled trial (RCT) in routine and specialist care settings.
• Copenhagen Clinic for Affective Disorder (MONARCA II research project)flagship — flagship clinical research collaboration underpinning monsenso's evidence baseStrategic or Co-development Partner · 1 September 2014MONARCA II is a randomised controlled single-blind parallel-group trial using the Monsenso system for daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder, with a feedback loop between patients and clinicians. The MONARCA system was originally EU-funded and is now further developed and supported by Monsenso.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Akili Interactive: Akili Interactive pioneered FDA-authorised digital therapeutics (EndeavorRx, EndeavorOS) for cognitive and mental health conditions. It shares Monsenso's regulated, evidence-led DTx positioning and targets similar enterprise healthcare buyers, payers and pharmaceutical partners.
• Big Health: Big Health is a prescription digital therapeutics company offering FDA-cleared Sleepio (insomnia) and Daylight (anxiety). It competes head-to-head with Monsenso in the regulated DTx category targeting mental health conditions with clinical-grade evidence and similar enterprise healthcare channels.
• SilverCloud Health (Amwell): SilverCloud Health, now part of Amwell, is an evidence-based digital mental health platform offering CBT-based programs to health systems and insurers with an extensive research base. It directly competes with Monsenso in the B2B mental health platform category, particularly with insurers and large healthcare systems.
• Limbic: Limbic is a UK-based AI mental health platform used by NHS Talking Therapies services for patient self-referral, triage and therapist decision support. It shares Monsenso's UK NHS focus and digital mental health positioning for public mental health providers.
• Mindstrong: Mindstrong pioneered the use of smartphone-collected digital biomarkers (typing patterns, screen behaviour, voice) to measure and manage mental health, sharing Monsenso's passive smartphone-sensor-based biomarker approach and clinical decision support positioning (Mindstrong later pivoted and wound down its original model).
• Meru Health: Meru Health is a digital mental health clinic offering evidence-based online programs for depression, anxiety and burnout with outcomes data and clinician support. Comparable to Monsenso as a clinically regulated, evidence-led B2B2C digital mental health platform serving employers and health plans.
• Pear Therapeutics (now Click Therapeutics): Pear Therapeutics was a leading prescription DTx company (reSET, reSET-O) for addiction and mental health before bankruptcy and asset sale to Click Therapeutics, which continues the model. A direct competitor to Monsenso in the regulated DTx space, especially given Monsenso's addiction and depression use cases.

Broad incumbents

• Calm Health: Calm Health is the clinical arm of the Calm meditation app, offering digital mental health programs to health systems, insurers and employers. It overlaps with Monsenso's enterprise mental health positioning but operates at consumer scale and competes for similar payer and employer relationships.
• Sword Health: Sword Health is a digital musculoskeletal care and DTx company that has expanded into broader digital care categories. Although not a direct mental-health competitor, it shares Monsenso's regulated, evidence-led DTx business model targeting enterprise buyers (employers, payers, providers) and demonstrates a comparable go-to-market playbook.
• Headspace Health: Headspace Health (combining Headspace and Ginger) is a broad mental health and wellness platform with consumer, employer and health-plan distribution. While much larger and consumer-led, it overlaps with Monsenso in the enterprise B2B mental health channel and competes for the same provider and pharma budgets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Monsenso
• Facebookfacebook.com/Monsenso
• LinkedInlinkedin.com/company/monsenso

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monsenso